Clinuvel Pharmaceuticals (CUV) H2 2026 earnings summary

Executive summary

• Achieved tenth consecutive year of profitability, with over AUD 100 million in revenue for the second year and strong cash reserves supporting U.S. expansion and strategic investments.

• Maintained disciplined financial management, remaining debt-free for 20 years and distributing dividends for nine consecutive years.

• Announced intention to delist from ASX and pursue a single listing on Nasdaq, with headquarters relocation to the U.S. in 2027.

• Continued expansion of R&D, especially in vitiligo and controlled release peptide platforms.

• U.S. now represents over 43% of global EPP revenues, with direct SCENESSEⓇ distribution expanding.

Financial highlights

• Revenues from ordinary activities reached AUD 94 million, with total income including interest at AUD 101 million; net profit after tax was AUD 34 million, down 6% year-over-year.

• Cash reserves increased by 12% to AUD 252 million, despite AUD 12 million in early tax payments.

• Gross profit margin was 83%, net profit margin 36%, and basic EPS at AUD 0.68, down 6%.

• Dividend per share declared at AUD 0.05, representing 9% of net free cash flow.

• Unrealized AUD 4 million FX translation loss due to currency fluctuations impacted net profit.

Outlook and guidance

• Focus on advancing pipeline, including Phase III vitiligo trials with topline data expected December 2026 and CUV107 trial readout anticipated in 2029.

• Continued disciplined capital deployment, no dilutive capital raisings for ten years, and expansion of U.S. operations with head office relocation effective January 2027.

• EPP business expected to grow at single-digit rates despite competition; targeting further market penetration in EPP and vitiligo.

• NEURACTHEL (ACTH) filing in Europe first, with U.S. filing to follow; revenue guidance post-regulatory review.

• Continued investment in R&D and infrastructure, including Singapore facility expansion.